Shares of Orasure (OSUR -15.6%) get slammed after coming up just shy of estimates on its Q3 top line late yesterday and lowering its Q4 guidance. The company says that sales of its infectious disease testing, substance abuse testing and insurance risk assessment products are running below projections, and it now expects a Q4 loss of $0.15 - $ 0.13 per share on revenues of $20.5M - $21M. Street expectations are for a loss of $0.07 on revenues of $24.28M.
Shares of Orasure (OSUR -15.6%) get slammed after coming up just shy of estimates on its Q3 top...
From other sites
Video at CNBC.com (May 19, 2015)
at CNBC.com (Nov 19, 2012)
at CNBC.com (Oct 23, 2012)
at CNBC.com (Oct 8, 2012)
at CNBC.com (Jul 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs